Case guide

A death after Dupixent use: questions for a claim check

If a loved one died after Dupixent use, ask a lawyer to check the cancer diagnosis and who may bring a claim. Drug use alone does not prove the cause of death.

See If You Qualify

Free · No obligation · About 2 minutes

Updated Oct 4, 20269 sources

This may apply to you if

  • These suggestions help you prepare for a claim check. They are not a firm's acceptance rules.
  • For preparation: note Dupixent use, the reason it was prescribed and the diagnosis you want checked. This does not decide whether a lawyer will accept the case.

What the public record says

These are cited sources. Their inclusion does not imply that they endorse People’s Justice or reviewed this page.

Matthew F. Kennelly · United States Judicial Panel on Multidistrict Litigation · Acting Chair, Judicial Panel on Multidistrict Litigation

Finding: Transferred listed CTCL actions to New Jersey under Judge Zahid N. Quraishi for coordinated pretrial proceedings; causation and warning adequacy remain disputed questions.

Dupixent JPML transfer order, June 4, 2026 (opens in a new tab) · Jun 4, 2026 · Checked Oct 3, 2026

The evidence and its limits

Memorial Sloan Kettering Cancer Center · Journal of the European Academy of Dermatology and Venereology · 2024

Cutaneous T-cell lymphoma and dupilumab use: matched outcomes

Design:
Cohort
Participants:
27 lymphoma patients with prior dupilumab and 27 matched lymphoma patients without it.
Finding:
No detected difference in survival or treatment outcomes.
Main limitation
Small selected cancer-center sample and limited follow-up; no causality or incidence analysis. Published online2024, issue2025.

Read the source: Cutaneous T-cell lymphoma and dupilumab use: matched outcomes (opens in a new tab) · Checked Oct 3, 2026

The short answer

What does the transfer order say about families?
The June 2026 order includes spouses and survivors of users diagnosed with skin T-cell cancer. Their claims are allegations, not findings of cause. [4]
How are a cancer diagnosis and cause of death different?
A cancer diagnosis does not by itself show that Dupixent caused a death. Ask a lawyer to check the care history and the evidence for that claim. [6]
Who may bring a claim for the person who died?
Ask a lawyer who may act for the family or estate. The law that applies to the claim decides who can bring it. [4]
What records could explain the illness and death?
Start with the death record, cancer test reports and drug dates. Ask which documents the family may obtain and who must request them. [3]

The process

What happens next

  1. 01

    You answer a few questions

    About two minutes. Nothing is sent until you agree on the last step and press submit.

  2. 02

    A lawyer looks at it

    A lawyer at the firm reads your answers and checks them against the current case criteria.

  3. 03

    The firm decides and gets in touch

    If the firm takes your case, you get the terms in writing to read before you sign. You can always say no.

What does the transfer order say about families?

The June 2026 order includes spouses and survivors of users diagnosed with skin T-cell cancer. Their claims are allegations, not findings of cause.

The cases allege that Dupixent caused or sped up cancer. The order sent listed cases to shared pretrial proceedings; it did not decide which family member can bring a claim under each law.

How are a cancer diagnosis and cause of death different?

A cancer diagnosis does not by itself show that Dupixent caused a death. Ask a lawyer to check the care history and the evidence for that claim.

A small study compared 27 cancer patients with prior drug use and 27 matched cancer patients without it. It found no clear survival difference. It did not test whether the drug caused any person's illness or death.

Give the lawyer the death record and care reports you have. Mark the difference between a diagnosis written by a clinician and a cause you suspect.

Who may bring a claim for the person who died?

Ask a lawyer who may act for the family or estate. The law that applies to the claim decides who can bring it.

Tell the lawyer where treatment occurred, where the person lived and whether anyone has been appointed to handle the estate. Ask which claim belongs to the estate and which may belong to relatives.

What records could explain the illness and death?

Start with the death record, cancer test reports and drug dates. Ask which documents the family may obtain and who must request them.

Health-record access has rules for personal representatives and deceased patients. The federal rule includes limits and exceptions; a relative should not assume unrestricted access to every note.

Keep original reports together with a list of treating offices. You can ask the lawyer to help identify missing periods rather than turning gaps into guessed medical events.

Is there a time limit for the family?

The time limit depends on the claim and law. Ask for a check using the death, diagnosis and treatment dates; do not wait for a group-case headline.

Give the lawyer any letters from courts or insurers. Ask whether the law uses a different starting date for the claim you are considering. The shared pretrial schedule is not a substitute for that check.

What fee questions should a family ask?

Ask for the fee and expense terms in writing. Ask who represents the family or estate, and what costs may be owed if the claim loses.

The model rule for a fee based on the result requires an explanation of percentages and expenses. It does not tell you a particular firm's fee or promise a recovery.

Before signing, ask which claim the agreement covers and who has authority to sign it. Keep the agreement with the estate papers and any court notices you already have.

Find out where you stand.

The review is free and private. Asking for it doesn’t commit you to anything.

Register your interest

Sources

  1. ABA Model Rule 1.5: feesABA Model Rule 1.5: fees
  2. Southern District of New York: time limitsSouthern District of New York: time limits · court
  3. 45 CFR 164.524: access to health records45 CFR 164.524: access to health records · regulator
  4. Dupixent JPML transfer order, June 4, 2026Dupixent JPML transfer order, June 4, 2026 · court
  5. Mandel et al: CTCL after dupilumab, 2024Mandel et al: CTCL after dupilumab, 2024 · study
  6. Stuver et al: matched CTCL outcomes, 2024 online/2025 issueStuver et al: matched CTCL outcomes, 2024 online/2025 issue · study
  7. FDA potential-signal table, information as of March 6, 2025FDA potential-signal table, information as of March 6, 2025 · regulator
  8. MedlinePlus: dupilumab injection, revised August 15, 2025MedlinePlus: dupilumab injection, revised August 15, 2025 · regulator
  9. HHS guidance on personal representativesHHS guidance on personal representatives · regulator

Checked against 9 primary sources by People's Justice editors · Updated

How we make money

People's Justice research team · Updated Oct 4, 2026